CagriSema Phase 3 Trial Completes Enrollment for Weight Loss in East Asia

The global prevalence of obesity and overweight continues to rise, posing significant public health challenges and increasing the risk of numerous comorbidities like type 2 diabetes and cardiovascular disease. While effective weight management therapies exist, there's a continuous need for more potent and well-tolerated options, especially for diverse populations. This study addresses the knowledge gap by specifically evaluating the efficacy and safety of the novel combination therapy CagriSema in East Asian participants.

As this is a recently completed Phase 3 clinical trial in terms of enrollment, specific efficacy and safety results are not yet publicly available. The study successfully enrolled its target of 331 East Asian participants, demonstrating the feasibility of conducting such a large-scale trial in this demographic. The primary outcome measure is designed to assess the percentage change in body weight from baseline, aiming to show significant weight reduction compared to placebo. Secondary outcomes will evaluate improvements in metabolic markers such as waist circumference and body mass index (BMI), alongside a comprehensive assessment of the incidence of adverse events and overall safety profile. > While specific efficacy and safety results are currently pending, the successful completion of enrollment marks a significant milestone for this CagriSema study.